伏立康唑序贯治疗侵袭性肺曲霉病的临床观察

Clinical efficacy of voriconazole in sequential treatment of invasive pulmonary aspergillosis

目的探讨伏立康唑序贯治疗侵袭性肺曲霉病的临床疗效及安全性,为改进临床治疗提供依据。方法选择2014年1月-2017年6月收治的侵袭性肺曲霉病患者192例,随机分为两组,其中对照组96例,按常规伏立康唑静脉治疗;观察组96例,给予伏立康唑静脉序贯口服治疗,对两组患者的临床疗效及不良反应进行观察比较。采用SPSS 13.0软件进行分析。结果观察组临床治愈率及总有效率分别为89.6%及92.7%,对照组分别为88.5%及93.8%,两组临床治愈率及总有效率差异无统计学意义。观察组不良反应发生率3.1%,明显低于对照组14.6%,差异有统计学意义(P﹤0.05)。结论伏立康唑静脉序贯口服给药治疗对侵袭性肺曲霉病的疗效良好,且降低了不良反应。

Objective To observe the clinica l efficacy and safety of voriconazole in sequential treatment ofinvasive pulmonary aspergillosis so as to provide guidance for clinical treatment. Methods A total of 192 patientswith invvsivv pulmonary aspergillosis fromjanuary 2014 to June 2017 were enrolled in the study and randomly divided into two groups. The control group （ n = 96 ） was treated with conventional intravenous administration of voriconqzole, while the observation group （ n = 96 ） was given the intravenous sequential oral administration of voriconazole. The improvement of symptoms,clinical efficacy,and adverse reactions were evaluated. The statistical analysis formed with the SPSS13. 0 software. Results The clinical cure rate was 89. 6% in the observation group and 88. 5% in the control group, and the total effective rate was 92. 7% in the observation group and 93. 8% in the control group. The difference in the clinical cure rate,the total effective rate,and improvement of symptgroups were no significant. The incidence of adverse reactions was 3. 1% in the observatcantly lower than 14. 6% in the control group （P 〈0. 05） . Conclusion The intravenous sequential oral administration of voriconazole is an highly effective and safe administration approach for tlie patients witli invasive pulmonary aspergillosis ,and it can reduce the incidence of adverse reaction.